Skip to main content
Omar Abdel-Wahab, MD, Oncology, New York, NY

OmarAbdel-WahabMD

Oncology • New York, NY

Hematologic Oncology

Physician

Request Appointment

Overview of Dr. Abdel-Wahab

Dr. Omar Abdel-Wahab is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Duke University School of Medicine and has been in practice 13 years. Dr. Abdel-Wahab accepts several types of health insurance, listed below. He is one of 503 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2004

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2007 - 2026
  • NJ State Medical License
    NJ State Medical License 2022 - 2025
  • MA State Medical License
    MA State Medical License 2006 - 2009
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias
    Omar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias
    Omar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
    Omar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • FDA Approves First Treatment for Patients with All Forms of Histiocytosis
    FDA Approves First Treatment for Patients with All Forms of HistiocytosisJanuary 30th, 2023
  • Nurix Therapeutics Presents Positive Clinical Results from Its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting
    Nurix Therapeutics Presents Positive Clinical Results from Its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual MeetingDecember 12th, 2022
  • Clinical Pathology Selected Abstracts
    Clinical Pathology Selected AbstractsJune 23rd, 2022
  • Join now to see all

Grant Support

  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Investigational Cancer Therapeutics Training Program (ICTTP)SLOAN-KETTERING INST CAN RESEARCH1977–2029
  • Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaFRED HUTCHINSON CANCER CENTER2023–2028
  • Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaFRED HUTCHINSON CANCER CENTER2023–2028
  • Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaFRED HUTCHINSON CANCER CENTER2023–2028
  • Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaFRED HUTCHINSON CANCER CENTER2023–2028
  • Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaFRED HUTCHINSON CANCER CENTER2023–2028
  • Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaFRED HUTCHINSON CANCER CENTER2023–2028
  • Synthetic introns for selective targeting of RNA splicing factor-mutant leukemiaFRED HUTCHINSON CANCER CENTER2023–2028
  • ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)SLOAN-KETTERING INST CAN RESEARCH2025–2026
  • Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkitWEILL MEDICAL COLL OF CORNELL UNIV2022–2026
  • Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkitWEILL MEDICAL COLL OF CORNELL UNIV2022–2026
  • The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2021–2026
  • The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2021–2026
  • The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2021–2026
  • The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2021–2026
  • The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2021–2026
  • The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaSLOAN-KETTERING INST CAN RESEARCH2021–2026
  • Interrogating the minor spliceosome to understand and treat leukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Interrogating the minor spliceosome to understand and treat leukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Interrogating the minor spliceosome to understand and treat leukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Interrogating the minor spliceosome to understand and treat leukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Interrogating the minor spliceosome to understand and treat leukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Targeting an RNA Binding Protein Network in Acute Myeloid LeukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Targeting an RNA Binding Protein Network in Acute Myeloid LeukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Interrogating the minor spliceosome to understand and treat leukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • Interrogating the minor spliceosome to understand and treat leukemiaSLOAN-KETTERING INST CAN RESEARCH2020–2025
  • MSK Paul Calabresi Career Development Award for Clinical OncologySLOAN-KETTERING INST CAN RESEARCH2015–2025
  • MSK Paul Calabresi Career Development Award for Clinical OncologySLOAN-KETTERING INST CAN RESEARCH2015–2025
  • MSK Paul Calabresi Career Development Award for Clinical OncologySLOAN-KETTERING INST CAN RESEARCH2015–2025
  • MSK Paul Calabresi Career Development Award for Clinical OncologySLOAN-KETTERING INST CAN RESEARCH2015–2025
  • MSK Paul Calabresi Career Development Award for Clinical OncologySLOAN-KETTERING INST CAN RESEARCH2015–2025
  • Genetic and molecular basis for SRSF2 mutations in myelodysplasiaFRED HUTCHINSON CANCER CENTER2015–2025
  • MSK Paul Calabresi Career Development Award for Clinical OncologySLOAN-KETTERING INST CAN RESEARCH2015–2025

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access PPO
    Anthem Blue Preferred HMO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Cofinity PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Choice
    First Health PPO
    GHI PPO
    Great West PPO
    Health Net Oregon PPO
    HealthAmerica HealthAssurance PPO
    Medical Mutual of Ohio SuperMed Plus
    Medical Mutual of Ohio SuperMed POS
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    ODS Network
    Oxford Health Freedom
    Oxford Health Liberty
    Regence Washington - Preferred Provider Network
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Omar Abdel-Wahab, Dr. Omar Abdel-Wahab, MD, Dr. O Abdel-Wahab